Sage Therapeutics (SAGE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SAGE Stock Forecast

Sage Therapeutics stock forecast is as follows: an average price target of $12.86 (represents a 129.23% upside from SAGE’s last price of $5.61) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.

SAGE Price Target

The average price target for Sage Therapeutics (SAGE) is $12.86 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $4.00. This represents a potential 129.23% upside from SAGE's last price of $5.61.

SAGE Analyst Ratings

Hold

According to 13 Wall Street analysts, Sage Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for SAGE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (23.08%), 9 'Hold' (69.23%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).

Sage Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 20, 2024	Brian Abrahams	RBC Capital	$4.00	$4.91	-18.53%	-28.70%
Oct 30, 2024	Yasmeen Rahimi	Piper Sandler	$26.00	$7.90	229.11%	363.46%
Oct 30, 2024	George Farmer	Scotiabank	$14.00	$8.48	65.09%	149.55%
Oct 30, 2024	Vamil Divan	Mizuho Securities	$10.00	$7.86	27.31%	78.25%
Oct 30, 2024	Douglas Tsao	H.C. Wainwright	$14.00	$8.48	65.09%	149.55%
Aug 14, 2024	Joon Lee	Truist Financial	$13.00	$7.95	63.52%	131.73%
Aug 06, 2024	Sumant Kulkarni	Canaccord Genuity	$9.00	$8.88	1.35%	60.43%
May 28, 2024	Joel Beatty	Robert W. Baird	$15.00	$11.93	25.73%	167.38%
Apr 25, 2024	Joon Lee	Truist Financial	$18.00	$13.58	32.55%	220.86%
Apr 18, 2024	George Farmer	Scotiabank	$19.00	$12.57	51.15%	238.68%
Apr 17, 2024	Jay Olson	Oppenheimer	$17.00	$12.57	35.24%	203.03%
Apr 17, 2024	Brian Abrahams	RBC Capital	$26.00	$12.12	114.52%	363.46%
Apr 17, 2024	Vamil Divan	Mizuho Securities	$20.00	$12.11	65.15%	256.51%
Apr 17, 2024	Salveen Richter	Goldman Sachs	$28.00	$12.11	131.21%	399.11%
Apr 17, 2024	Joon Lee	Truist Financial	$22.00	$12.32	78.57%	292.16%
Dec 06, 2022		J.P. Morgan	$60.00	$40.99	46.38%	969.52%
Nov 11, 2022		Guggenheim	$48.00	$35.27	36.09%	755.61%
Jun 20, 2022	Yasmeen Rahimi	Piper Sandler	$100.00	$33.86	195.33%	1682.53%
May 04, 2022		RBC Capital	$35.00	$32.79	6.74%	523.89%
Feb 25, 2022	Gary Nachman	BMO Capital	$48.00	$36.65	30.97%	755.61%
Feb 24, 2022	Brian Abrahams	RBC Capital	$37.00	$34.71	6.60%	559.54%
Feb 24, 2022	Paul Matteis	Stifel Nicolaus	$58.00	$34.71	67.10%	933.87%
Feb 24, 2022	Marc Goodman	Leerink Partners	$50.00	$34.71	44.05%	791.27%
Feb 17, 2022	Jay Olson	Oppenheimer	$74.00	$33.58	120.37%	1219.07%
Nov 02, 2021	Yatin Suneja	Guggenheim	$55.00	$43.57	26.23%	880.39%
Oct 06, 2021	Akash Tewari	Jefferies	$50.00	$45.64	9.55%	791.27%
Aug 03, 2021	Laura Chico	Wedbush	$80.00	$41.76	91.57%	1326.02%
Jun 16, 2021	Neena Bitritto-Garg	Citigroup	$68.00	$54.88	23.91%	1112.12%
Jun 15, 2021	Ritu Baral	Cowen & Co.	$105.00	$58.80	78.57%	1771.66%

The latest Sage Therapeutics stock forecast, released on Nov 20, 2024 by Brian Abrahams from RBC Capital, set a price target of $4.00, which represents a -18.53% decrease from the stock price at the time of the forecast ($4.91), and a -28.70% decrease from SAGE last price ($5.61).

Sage Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	5	15
Avg Price Target	$4.00	$13.60	$17.00
Last Closing Price	$5.61	$5.61	$5.61
Upside/Downside	-28.70%	142.42%	203.03%

In the current month, the average price target of Sage Therapeutics stock is $4.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -28.70% decrease as opposed to Sage Therapeutics's last price of $5.61. This month's average price target is down -70.59% compared to last quarter, and down -76.47% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 20, 2024	RBC Capital	Underperform	Sector Perform	Upgrade
Oct 30, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 30, 2024	Scotiabank	Outperform	Outperform	Hold
Oct 30, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Oct 30, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Oct 04, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Oct 04, 2024	RBC Capital	Underperform	Underperform	Hold
Oct 04, 2024	RBC Capital	Underperform	Sector Perform	Downgrade
Jul 30, 2024	J.P. Morgan	Underperform	Underperform	Hold
Jul 30, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Jul 30, 2024	Cowen & Co.	Buy	Hold	Downgrade
Jul 12, 2024	Scotiabank	Underperform	Underperform	Hold
Jul 12, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Jun 20, 2024	Scotiabank	Underperform	Underperform	Hold
Jun 20, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Jun 13, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Jun 12, 2024	Bank of America Securities	Underperform	Underperform	Hold
Jun 11, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 11, 2024	Citigroup	Sell	Sell	Hold
May 29, 2024	Wedbush	Sector Perform	Sector Perform	Hold
May 29, 2024	Scotiabank	Underperform	Underperform	Hold
May 28, 2024	Citigroup		Sell	Initialise
Apr 18, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Apr 18, 2024	RBC Capital	Underperform	Underperform	Hold
Apr 18, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Apr 17, 2024	Oppenheimer	Perform	Perform	Hold
Apr 17, 2024	Cowen & Co.	Buy	Buy	Hold
Apr 17, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Apr 17, 2024	William Blair	Market Perform	Market Perform	Hold
Apr 17, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Apr 17, 2024	Goldman Sachs	Neutral	Neutral	Hold
Apr 17, 2024	Raymond James	Market Perform	Market Perform	Hold
Feb 15, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Aug 07, 2023	Needham	Buy	Buy	Hold
Aug 07, 2023	RBC Capital	Outperform	Sector Perform	Downgrade
Mar 13, 2023	RBC Capital		Outperform	Upgrade
Jan 03, 2023	Guggenheim	Buy	Neutral	Downgrade
Nov 11, 2022	Guggenheim	Buy	Buy	Hold
Jun 20, 2022	Piper Sandler	Overweight	Overweight	Hold
Feb 25, 2022	SVB Leerink	Market Perform	Market Perform	Hold

Sage Therapeutics's last stock rating was published by RBC Capital on Nov 20, 2024. The company Upgrade its SAGE rating from "Underperform" to "Sector Perform".

Sage Therapeutics Financial Forecast

Sage Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.72M	$2.47M	$3.29M	$2.87M	$1.74M	$1.50M	$1.58M	$1.64M	$1.44M	$1.64M	$1.58M	$1.11B	$1.64M	$1.09M	$2.29M	$1.96M	$3.57M
Avg Forecast	$72.70M	$44.60M	$37.16M	$31.50M	$22.74M	$20.02M	$17.99M	$15.99M	$14.11M	$10.80M	$8.85M	$5.26M	$61.03M	$4.63M	$2.94M	$2.37M	$2.00M	$1.64M	$1.76M	$3.23M	$1.78M	$1.96M	$2.00M	$2.03M	$1.95M	$1.84M	$877.19K	$2.78M	$3.66M	$2.77M
High Forecast	$108.62M	$66.63M	$55.53M	$47.06M	$33.98M	$29.91M	$26.87M	$26.01M	$17.27M	$11.03M	$8.85M	$5.26M	$130.59M	$32.08M	$4.39M	$3.54M	$2.99M	$1.64M	$1.76M	$3.23M	$1.78M	$1.96M	$2.00M	$2.03M	$1.95M	$1.84M	$877.19K	$2.78M	$3.66M	$2.77M
Low Forecast	$41.51M	$25.46M	$21.22M	$17.98M	$12.98M	$11.43M	$10.27M	$8.08M	$10.39M	$10.57M	$8.85M	$5.26M	$2.61M	$1.00M	$1.68M	$1.35M	$1.14M	$1.64M	$1.76M	$3.23M	$1.78M	$1.96M	$2.00M	$2.03M	$1.95M	$1.84M	$877.19K	$2.78M	$3.66M	$2.77M
# Analysts	3	3	3	3	4	4	4	6	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.59%	0.84%	1.39%	1.43%	1.06%	0.85%	0.49%	0.92%	0.74%	0.82%	0.78%	568.34%	0.89%	1.24%	0.82%	0.54%	1.29%

Sage Therapeutics's average Quarter revenue forecast for Dec 23 based on 12 analysts is $61.03M, with a low forecast of $2.61M, and a high forecast of $130.59M. SAGE's average Quarter revenue forecast represents a 2147.22% increase compared to the company's last Quarter revenue of $2.72M (Sep 23).

Sage Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-144.32M	$-170.46M	$-155.47M	$-153.90M	$-141.20M	$-128.13M	$-122.92M	$-124.38M	$-129.80M	$-106.35M	$-93.18M	$975.54M	$-105.08M	$-135.69M	$-126.07M	$-167.99M	$-179.26M
Avg Forecast	$-49.98M	$-30.66M	$-25.55M	$-21.65M	$-15.64M	$-13.76M	$-12.37M	$-11.00M	$-9.70M	$-7.42M	$-6.09M	$-122.23M	$-41.96M	$-3.18M	$-2.02M	$-111.11M	$-139.97M	$-1.12M	$-1.20M	$-118.84M	$-1.21M	$-1.34M	$-1.36M	$-106.35M	$-1.33M	$-1.26M	$-599.14K	$-154.18M	$-2.50M	$-1.89M
High Forecast	$-28.54M	$-17.51M	$-14.59M	$-12.36M	$-8.93M	$-7.86M	$-7.06M	$-5.56M	$-7.14M	$-7.27M	$-6.09M	$-97.78M	$-1.80M	$-689.33K	$-1.15M	$-88.89M	$-111.98M	$-1.12M	$-1.20M	$-95.07M	$-1.21M	$-1.34M	$-1.36M	$-85.08M	$-1.33M	$-1.26M	$-599.14K	$-123.34M	$-2.50M	$-1.89M
Low Forecast	$-74.68M	$-45.81M	$-38.18M	$-32.35M	$-23.36M	$-20.56M	$-18.47M	$-17.88M	$-11.87M	$-7.58M	$-6.09M	$-146.67M	$-89.78M	$-22.06M	$-3.02M	$-133.34M	$-167.96M	$-1.12M	$-1.20M	$-142.61M	$-1.21M	$-1.34M	$-1.36M	$-127.63M	$-1.33M	$-1.26M	$-599.14K	$-185.01M	$-2.50M	$-1.89M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	45.32%	84.38%	1.40%	1.10%	125.70%	106.38%	1.03%	102.38%	97.06%	78.04%	0.88%	-731.84%	83.54%	226.47%	0.82%	67.25%	94.65%

4 analysts predict SAGE's average Quarter EBITDA for Mar 21 to be $-106.35M, with a high of $-85.08M and a low of $-127.63M. This is -110.90% lower than Sage Therapeutics's previous annual EBITDA (Dec 20) of $975.54M.

Sage Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-201.63M	$-160.32M	$-138.19M	$-133.31M	$-129.04M	$-122.01M	$-119.74M	$-124.71M	$-130.17M	$-107.25M	$-95.76M	$974.89M	$-105.73M	$-136.35M	$-126.74M	$-168.65M	$-179.96M
Avg Forecast	$-36.06M	$-58.67M	$-61.73M	$-63.56M	$-64.94M	$-68.07M	$-72.25M	$-76.94M	$-93.71M	$-94.27M	$-100.30M	$-123.69M	$-78.02M	$-163.98M	$-156.09M	$-112.44M	$-140.34M	$-134.17M	$-129.21M	$-120.26M	$-129.11M	$-111.41M	$-101.11M	$-109.30M	$-126.16M	$-139.37M	$-154.88M	$-154.99M	$-216.04M	$-206.19M
High Forecast	$-15.94M	$-25.94M	$-27.29M	$-28.11M	$-28.71M	$-30.10M	$-31.95M	$-64.32M	$-61.04M	$-41.68M	$-44.35M	$-98.95M	$35.04M	$-89.50M	$-69.02M	$-89.95M	$-112.28M	$-134.17M	$-129.21M	$-96.21M	$-129.11M	$-111.41M	$-101.11M	$-87.44M	$-126.16M	$-139.37M	$-154.88M	$-124.00M	$-216.04M	$-206.19M
Low Forecast	$-59.22M	$-96.35M	$-101.37M	$-104.38M	$-106.64M	$-111.78M	$-118.66M	$-92.57M	$-125.16M	$-154.81M	$-164.71M	$-148.42M	$-169.27M	$-204.23M	$-256.33M	$-134.93M	$-168.41M	$-134.17M	$-129.21M	$-144.31M	$-129.11M	$-111.41M	$-101.11M	$-131.16M	$-126.16M	$-139.37M	$-154.88M	$-185.99M	$-216.04M	$-206.19M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.23%	1.03%	1.23%	0.95%	0.96%	0.94%	1.00%	0.97%	1.17%	1.06%	0.88%	-7.73%	0.76%	0.88%	0.82%	0.78%	0.87%

Sage Therapeutics's average Quarter net income forecast for Mar 21 is $-109.30M, with a range of $-131.16M to $-87.44M. SAGE's average Quarter net income forecast represents a -111.21% decrease compared to the company's last Quarter net income of $974.89M (Dec 20).

Sage Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$78.14M	$75.56M	$65.71M	$67.33M	$61.48M	$52.41M	$46.48M	$51.60M	$48.71M	$43.35M	$39.85M	$53.50M	$35.10M	$38.22M	$70.13M	$85.13M	$88.50M
Avg Forecast	$1.63B	$1.00B	$835.57M	$708.11M	$511.29M	$450.02M	$404.37M	$359.57M	$317.17M	$242.79M	$199.00M	$118.28M	$1.37B	$104.14M	$66.06M	$53.34M	$45.01M	$36.98M	$39.65M	$72.56M	$39.99M	$44.02M	$44.86M	$45.56M	$43.88M	$41.40M	$19.72M	$62.51M	$82.23M	$62.34M
High Forecast	$2.44B	$1.50B	$1.25B	$1.06B	$763.89M	$672.35M	$604.14M	$584.72M	$388.27M	$247.90M	$199.01M	$118.28M	$2.94B	$721.33M	$98.70M	$79.70M	$67.24M	$36.98M	$39.65M	$72.56M	$39.99M	$44.02M	$44.86M	$45.56M	$43.88M	$41.40M	$19.72M	$62.51M	$82.23M	$62.34M
Low Forecast	$933.14M	$572.44M	$477.03M	$404.27M	$291.90M	$256.92M	$230.86M	$181.66M	$233.64M	$237.67M	$199.00M	$118.27M	$58.72M	$22.54M	$37.72M	$30.45M	$25.70M	$36.98M	$39.65M	$72.56M	$39.99M	$44.02M	$44.86M	$45.56M	$43.88M	$41.40M	$19.72M	$62.51M	$82.23M	$62.34M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	1.14%	1.23%	1.50%	1.66%	1.32%	0.64%	1.29%	1.11%	0.97%	0.87%	1.22%	0.85%	1.94%	1.12%	1.04%	1.42%

Sage Therapeutics's average Quarter SG&A projection for Dec 23 is $1.37B, based on 12 Wall Street analysts, with a range of $58.72M to $2.94B. The forecast indicates a 1656.05% rise compared to SAGE last annual SG&A of $78.14M (Sep 23).

Sage Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	3	3	3	3	4	4	4	6	14	9	6	6	12	20	10	10	9	9	9	9	10	10	10	4	5	4	5	4	4	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.37	$-2.68	$-2.32	$-2.24	$-2.17	$-2.06	$-2.03	$-2.12	$-2.21	$-1.83	$-1.64	$18.71	$-2.03	$-2.63	$-2.44	$-3.25	$-3.48
Avg Forecast	$-0.59	$-0.96	$-1.01	$-1.04	$-1.06	$-1.11	$-1.18	$-1.26	$-1.53	$-1.54	$-1.64	$-1.65	$-1.28	$-2.68	$-2.55	$-2.51	$-2.38	$-2.22	$-2.13	$-2.06	$-2.13	$-1.84	$-1.67	$-1.87	$-2.08	$-2.30	$-2.56	$-3.02	$-3.57	$-3.41
High Forecast	$-0.26	$-0.42	$-0.45	$-0.46	$-0.47	$-0.49	$-0.52	$-1.05	$-1.00	$-0.68	$-0.73	$-0.73	$0.57	$-1.46	$-1.13	$-1.11	$-1.05	$-2.22	$-2.13	$-2.06	$-2.13	$-1.84	$-1.67	$-1.87	$-2.08	$-2.30	$-2.56	$-3.02	$-3.57	$-3.41
Low Forecast	$-0.97	$-1.58	$-1.66	$-1.71	$-1.74	$-1.83	$-1.94	$-1.51	$-2.05	$-2.53	$-2.70	$-2.71	$-2.77	$-3.34	$-4.19	$-4.12	$-3.90	$-2.22	$-2.13	$-2.06	$-2.13	$-1.84	$-1.67	$-1.87	$-2.08	$-2.30	$-2.56	$-3.02	$-3.57	$-3.41
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.26%	1.05%	0.93%	0.94%	0.98%	0.97%	0.99%	0.99%	1.20%	1.10%	0.88%	-8.98%	0.88%	1.03%	0.81%	0.91%	1.02%

According to 4 Wall Street analysts, Sage Therapeutics's projected average Quarter EPS for Mar 21 is $-1.87, with a low estimate of $-1.87 and a high estimate of $-1.87. This represents a -110.01% decrease compared to SAGE previous annual EPS of $18.71 (Dec 20).

Sage Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
ARVN	Arvinas	$19.10	$58.50	206.28%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
SAGE	Sage Therapeutics	$5.27	$12.86	144.02%	Hold
IMCR	Immunocore	$29.40	$70.20	138.78%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
DMAC	DiaMedica Therapeutics	$5.20	$8.50	63.46%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
NUVL	Nuvalent	$88.10	$114.80	30.31%	Buy
INCY	Incyte	$69.40	$90.11	29.84%	Buy
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy
ALNY	Alnylam Pharmaceuticals	$246.58	$310.60	25.96%	Buy
KRYS	Krystal Biotech	$169.04	$210.33	24.43%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy

SAGE Forecast FAQ

Is Sage Therapeutics a good buy?

No, according to 13 Wall Street analysts, Sage Therapeutics (SAGE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 23.08% of SAGE's total ratings.

What is SAGE's price target?

Sage Therapeutics (SAGE) average price target is $12.86 with a range of $4 to $26, implying a 129.23% from its last price of $5.61. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sage Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SAGE stock, the company can go up by 129.23% (from the last price of $5.61 to the average price target of $12.86), up by 363.46% based on the highest stock price target, and down by -28.70% based on the lowest stock price target.

Can Sage Therapeutics stock reach $8?

SAGE's average twelve months analyst stock price target of $12.86 supports the claim that Sage Therapeutics can reach $8 in the near future.

What is Sage Therapeutics's current price target trend?

1 Wall Street analyst forecast a $4 price target for Sage Therapeutics (SAGE) this month, down -28.70% from its last price of $5.61. Compared to the last 3 and 12 months, the average price target increased by 142.42% and increased by 203.03%, respectively.

What are Sage Therapeutics's analysts' financial forecasts?

Sage Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $76.74M (high $116.76M, low $42.76M), average EBITDA is $-52.759M (high $-29.398M, low $-80.276M), average net income is $-282M (high $-155M, low $-430M), average SG&A $1.73B (high $2.63B, low $961.35M), and average EPS is $-4.617 (high $-2.537, low $-7.03). SAGE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $185.96M (high $277.83M, low $106.17M), average EBITDA is $-128M (high $-72.992M, low $-191M), average net income is $-220M (high $-97.289M, low $-361M), average SG&A $4.18B (high $6.25B, low $2.39B), and average EPS is $-3.6 (high $-1.592, low $-5.912).

Did the SAGE's actual financial results beat the analysts' financial forecasts?

Based on Sage Therapeutics's last annual report (Dec 2023), the company's revenue was $86.46M, beating the average analysts forecast of $70.98M by 21.81%. Apple's EBITDA was $-580M, beating the average prediction of $-158M by 266.34%. The company's net income was $-541M, beating the average estimation of $-511M by 6.06%. Apple's SG&A was $274.52M, missing the average forecast of $1.6B by -82.80%. Lastly, the company's EPS was $-0.009, missing the average prediction of $-9.02 by -99.90%. In terms of the last quarterly report (Sep 2023), Sage Therapeutics's revenue was $2.72M, missing the average analysts' forecast of $4.63M by -41.37%. The company's EBITDA was $-144M, beating the average prediction of $-3.185M by 4431.69%. Sage Therapeutics's net income was $-202M, beating the average estimation of $-164M by 22.96%. The company's SG&A was $78.14M, missing the average forecast of $104.14M by -24.97%. Lastly, the company's EPS was $-3.37, beating the average prediction of $-2.683 by 25.60%